TCM
PTGX icon

Triumph Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Triumph Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21K Hold
18
– – ﹤0.01% 1557
2026
Q1 		$1.9K Hold
18
– – ﹤0.01% 1544
2025
Q4 		$1.57K Buy
+18
New +$1.47K ﹤0.01% 1502

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Triumph Capital Management's PTGX Position: Q2 2026 in Review

Triumph Capital Management held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 18 shares worth $2.21K. The position accounts for ﹤0.01% of the portfolio, ranked #1557.

Triumph Capital Management first reported a position in PTGX in Q4 2025 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Triumph Capital Management held 18 shares of Protagonist Therapeutics worth $2.21K as of Q2 2026.
  • Triumph Capital Management left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1557 holding.
  • Triumph Capital Management first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.